Loading...
Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) has been a model disease in the development of targeted therapies. After nearly 40 years of the recognition of the chromosomal abnormality that defines CML, specific therapy was developed, initially with imatinib mesylate, which has transformed our treatment algorithms...
Saved in:
| Published in: | J Clin Oncol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society of Clinical Oncology
2011
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4979134/ https://ncbi.nlm.nih.gov/pubmed/21220597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.3619 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|